Rarecells
Latest round
- Series A
Last raised
- Jul 2021
Total raised
- $8M
Investors
- 2
About Rarecells
Rarecells, founded in 2010 in Paris, France, specializes in liquid biopsy solutions aimed at cancer diagnostics. The company has not undergone notable pivots or changes in its business strategy since its inception.Rarecells specializes in innovative liquid biopsy technology, primarily through its flagship product, the ISET® technology, which enables the early detection of cancer by analyzing blood samples. This non-invasive method captures early signals of cancer by identifying circulating tumor cells (CTCs) in bodily fluids, providing a significant advantage over traditional tissue biopsies. The ISET® technology has been developed over more than a decade and is CE-IVD certified, making it suitable for clinical applications across various cancer types. Rarecells collaborates with diagnostic and pharmaceutical companies to enhance the accessibility of their tests, primarily targeting markets in the United States and Europe.Rarecells generates revenue through partnerships and collaborations with diagnostic and pharmaceutical companies that utilize its ISET® technology in their cancer detection and treatment protocols. The transaction structure is primarily B2B, where healthcare organizations purchase services based on their specific needs for cancer diagnostics. Pricing plans for the ISET® technology are structured around the volume of tests ordered and the scope of service agreements established with partner organizations. This model allows Rarecells to scale its offerings according to demand, ensuring that healthcare providers have access to cutting-edge cancer detection tools. The company aims to expand its market presence by introducing its innovative diagnostic tests to healthcare providers across North America, with plans to commence these operations in the near future.
Who invested in Rarecells
2 investors across 1 round
See all investors in Rarecells
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 22, 2021
Amount
$8M
Investors
Questions about Rarecells
Who invested in Rarecells?
Rarecells has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Rarecells raised?
Rarecells has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Rarecells last raise money?
Rarecells's most recent round on record is a Series A, in Jul 2021.
What does Rarecells do?
Rarecells, founded in 2010 in Paris, France, specializes in liquid biopsy solutions aimed at cancer diagnostics.
Where is Rarecells headquartered?
Rarecells is headquartered in Paris, France.
Which VCs invest in companies like Rarecells?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Rarecells's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Rarecells? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.